Zastosowanie sztucznej inteligencji w immunoterapii nowotworów

Didkowska J, Wojciechowska U, Michalek IM, Caetano Dos Santos FL. Cancer incidence and mortality in Poland in 2019. Sci Rep. 2022;12(1):10875. Published 2022 Jun 27. doi:10.1038/s41598-022-14779-6

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul;70(4):313]. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492

Golemis EA, Scheet P, Beck TN, et al. Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev. 2018;32(13-14):868-902. doi:10.1101/gad.314849.118

Ramesh AN, Kambhampati C, Monson JR, Drew PJ. Artificial intelligence in medicine. Ann R Coll Surg Engl. 2004;86(5):334-338. doi:10.1308/147870804290

Hamet P, Tremblay J. Artificial intelligence in medicine. Metabolism. 2017;69S:S36-S40. doi:10.1016/j.metabol.2017.01.011

Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):396. Published 2019 Sep 9. doi:10.1186/s13046-019-1396-4

Wahyuhadi J, Immadoel Haq IB, Arifianto MR, et al. Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-Analysis. Cancer Control. 2022;29:10732748221079474. doi:10.1177/10732748221079474

Mitra S, Li G, Harsh GR 4th. Passive antibody-mediated immunotherapy for the treatment of malignant gliomas. Neurosurg Clin N Am. 2010;21(1):67-76. doi:10.1016/j.nec.2009.08.010

Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269-281. Published 2012 Mar 22. doi:10.1038/nri3191

Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14(11):655-668. doi:10.1038/nrclinonc.2017.88

Soularue E, Lepage P, Colombel JF, et al. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut. 2018;67(11):2056-2067. doi:10.1136/gutjnl-2018-316948

Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013;25(2):261-267. doi:10.1016/j.coi.2013.03.004

Mekki A, Dercle L, Lichtenstein P, et al. Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy. Eur J Cancer. 2019;119:44-56. doi:10.1016/j.ejca.2019.06.020

Martins J, Magalhães C, Rocha M, Osório NS. Machine Learning-Enhanced T Cell Neoepitope Discovery for Immunotherapy Design. Cancer Inform. 2019;18:1176935119852081. Published 2019 May 23. doi:10.1177/1176935119852081

Langs G, Röhrich S, Hofmanninger J, et al. Machine learning: from radiomics to discovery and routine. Maschinelles Lernen: von Radiomics zu Forschung und Routine. Radiologe. 2018;58(Suppl 1):1-6. doi:10.1007/s00117-018-0407-3

Kleppe A, Skrede OJ, De Raedt S, Liestøl K, Kerr DJ, Danielsen HE. Designing deep learning studies in cancer diagnostics. Nat Rev Cancer. 2021;21(3):199-211. doi:10.1038/s41568-020-00327-9

Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJWL. Artificial intelligence in radiology. Nat Rev Cancer. 2018;18(8):500-510. doi:10.1038/s41568-018-0016-5

Kooi T, Litjens G, van Ginneken B, et al. Large scale deep learning for computer aided detection of mammographic lesions. Med Image Anal. 2017;35:303-312. doi:10.1016/j.media.2016.07.007

Trebeschi S, Drago SG, Birkbak NJ, et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol. 2019;30(6):998-1004. doi:10.1093/annonc/mdz108

Sirinukunwattana K, Ahmed Raza SE, Yee-Wah Tsang, Snead DR, Cree IA, Rajpoot NM. Locality Sensitive Deep Learning for Detection and Classification of Nuclei in Routine Colon Cancer Histology Images. IEEE Trans Med Imaging. 2016;35(5):1196-1206. doi:10.1109/TMI.2016.2525803

Kather JN, Pearson AT, Halama N, et al. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat Med. 2019;25(7):1054-1056. doi:10.1038/s41591-019-0462-y

Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-2520. doi:10.1056/NEJMoa1500596

Zaitsev A, Chelushkin M, Dyikanov D, et al. Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. Cancer Cell. 2022;40(8):879-894.e16. doi:10.1016/j.ccell.2022.07.006

Kuksin M, Morel D, Aglave M, et al. Applications of single-cell and bulk RNA sequencing in onco-immunology. Eur J Cancer. 2021;149:193-210. doi:10.1016/j.ejca.2021.03.005

Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753. doi:10.1016/j.pharmthera.2020.107753

Ji RR, Chasalow SD, Wang L, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother. 2012;61(7):1019-1031. doi:10.1007/s00262-011-1172-6

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355. doi:10.1126/science.aar4060

Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015;33(17):1974-1982. doi:10.1200/JCO.2014.59.4358

Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582-598. doi:10.1038/nrc.2016.73

Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335-348. doi:10.1016/j.cell.2005.02.034

Lakins MA, Ghorani E, Munir H, Martins CP, Shields JD. Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells. Nat Commun. 2018;9(1):948. Published 2018 Mar 5. doi:10.1038/s41467-018-03347-0

DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369-382. doi:10.1038/s41577-019-0127-6

Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27(4):462-472. doi:10.1016/j.ccell.2015.02.015

Chen FH, Chiang CS, Wang CC, et al. Radiotherapy decreases vascular density and causes hypoxia with macrophage aggregation in TRAMP-C1 prostate tumors. Clin Cancer Res. 2009;15(5):1721-1729. doi:10.1158/1078-0432.CCR-08-1471

Hughes R, Qian BZ, Rowan C, et al. Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. Cancer Res. 2015;75(17):3479-3491. doi:10.1158/0008-5472.CAN-14-3587

Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity [published correction appears in Nat Rev Cancer. 2017 Aug 24;17 (9):569]. Nat Rev Cancer. 2017;17(4):209-222. doi:10.1038/nrc.2016.154

Tran E, Ahmadzadeh M, Lu YC, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350(6266):1387-1390. doi:10.1126/science.aad1253

Bjerregaard AM, Nielsen M, Hadrup SR, Szallasi Z, Eklund AC. MuPeXI: prediction of neo-epitopes from tumor sequencing data. Cancer Immunol Immunother. 2017;66(9):1123-1130. doi:10.1007/s00262-017-2001-3

Bulik-Sullivan B, Busby J, Palmer CD, et al. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification [published online ahead of print, 2018 Dec 17]. Nat Biotechnol. 2018;10.1038/nbt.4313. doi:10.1038/nbt.4313

de Sousa E, Lérias JR, Beltran A, et al. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery. Front Immunol. 2021;12:592031. Published 2021 Jul 15. doi:10.3389/fimmu.2021.592031

Liu G, Zeng H, Mueller J, et al. Antibody complementarity determining region design using high-capacity machine learning. Bioinformatics. 2020;36(7):2126-2133. doi:10.1093/bioinformatics/btz895

Weitzner BD, Dunbrack RL Jr, Gray JJ. The origin of CDR H3 structural diversity. Structure. 2015;23(2):302-311. doi:10.1016/j.str.2014.11.010

Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies (Basel). 2019;8(4):55. Published 2019 Dec 3. doi:10.3390/antib8040055

Akpinaroglu D, Ruffolo JA, Mahajan SP, Gray JJ. Simultaneous prediction of antibody backbone and side-chain conformations with deep learning. PLoS One. 2022;17(6):e0258173. Published 2022 Jun 15. doi:10.1371/journal.pone.0258173

Feng J, Jiang M, Shih J, Chai Q. Antibody apparent solubility prediction from sequence by transfer learning. iScience. 2022;25(10):105173. Published 2022 Sep 22. doi:10.1016/j.isci.2022.105173

Agrawal NJ, Helk B, Kumar S, et al. Computational tool for the early screening of monoclonal antibodies for their viscosities. MAbs. 2016;8(1):43-48. doi:10.1080/19420862.2015.1099773

Prihoda D, Maamary J, Waight A, et al. BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning. MAbs. 2022;14(1):2020203. doi:10.1080/19420862.2021.2020203